Endogenous retroviruses (ERVs) are genomic elements that are normally kept inactive through epigenetic mechanisms. Under conditions of immune deficiency, however, ERVs can be reactivated and contribute to oncogenic processes. The physiological triggers and microenvironmental mechanisms that drive ERV-mediated tumorigenesis in vivo have not been fully defined. This study investigated the role of B cell receptor (BCR) signaling in reactivating ERVs and promoting lymphomagenesis in a T-cell-deficient mouse strain.
The work was performed in T-cell-deficient B6-Ly5.1 mice. The study examined relationships among BCR activation, ERV reactivation (specifically Emv10), tumor phenotype, proviral insertion events, and the influence of T cell deficiency on tumor development and spread. Specific experimental details (numbers of animals, timing, genetic constructs, and methods) were not reported in the abstract and therefore are not available from the provided source text.
The authors report that BCR signaling triggers reactivation of the endogenous retrovirus Emv10 in this model. Reactivation of Emv10 was associated with the emergence of B cell tumors that exhibit a germinal center B cell-like (GCL) phenotype. These tumors displayed somatic hypermutations consistent with a germinal center history. The findings link antigen receptor signaling in B cells to ERV activation and a specific B cell lymphoma phenotype in the context of T-cell deficiency.
Tumors arising in the model harbored recurrent endogenous murine leukemia virus (eMLV) proviral insertions near the Plch2 locus on chromosome 4. These insertion events were associated with aberrant activation of Plch2. The presence of recurrent proviral insertions near a specific locus suggests insertional mutagenesis as a cooperating mechanism in tumor development in this setting.
Chronic in vivo antigen stimulation using NP-Ficoll significantly accelerated development of lethal germinal center-like B cell (GCL) tumors in these mice. Acceleration of disease following chronic antigen engagement was accompanied by systemic accumulation of malignant cells, indicating that persistent BCR engagement promotes not only initiation but also dissemination of malignant B cells in the T-cell-deficient host.
To probe whether direct BCR activation of a specific clone was required for tumor origin, the authors used a system in which direct BCR stimulation was restricted to a minor subset of λ+ B cells. Unexpectedly, the accelerated malignancies that developed after stimulation arose predominantly from non-stimulated λ- B cell clones. This observation supports a non-cell-autonomous mechanism: physiological BCR activation in a subset of B cells can foster conditions that enable malignant transformation of other, unstimulated B cell clones within the host.
A central conclusion is that T cell–mediated immune surveillance normally restricts ERV-driven tumor propagation across the host B cell compartment. In the T-cell-deficient B6-Ly5.1 mice, loss of T cell surveillance allowed ERV reactivation and subsequent propagation of malignant clones, implicating T cells as a barrier to ERV-associated lymphomagenesis.
The study defines a pathway in which physiological BCR activation triggers reactivation of a specific ERV (Emv10), which, together with recurrent eMLV proviral insertions near Plch2, somatic hypermutation, and chronic antigen exposure, promotes the development of lethal germinal center B cell-like lymphomas in a T-cell-deficient mouse strain. The finding that malignancies can arise non-cell-autonomously from non-stimulated clones shifts the perspective on how localized BCR engagement can influence the broader B cell compartment. The data emphasize the importance of intact T cell surveillance in preventing ERV-driven B cell malignancies.
The abstract does not provide experimental details such as sample sizes, exact timelines, quantitative measures of ERV reactivation, sequencing depth for proviral insertions, or the molecular assays used to document Plch2 activation. Specifics of the λ+ versus λ- stimulation model, statistical analyses, and potential therapeutic implications beyond the conceptual mechanism were not reported in the source abstract and therefore cannot be inferred here.
These observations provide a framework for future mechanistic work to detail molecular steps linking BCR engagement, ERV reactivation, insertional mutagenesis, and immune surveillance in B cell oncogenesis.